SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Oct 15, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its third quarter 2025 financial results before the market opens on Wednesday, October 29, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast... Read More

SILVER SPRING, Md., & RESEARCH TRIANGLE PARK, N.C. / Oct 13, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced two presentations at the upcoming CHEST 2025 Annual Meeting hosted by the American College of Chest Physicians taking place October 19-22, 2025, in Chicago. In addition, United Therapeutics will sponsor and host several events including the PHinding... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 19, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will host a webcast to review data from the successful TETON-2 pivotal study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of idiopathic pulmonary fibrosis ( IPF ) on Sunday, September 28, 2025, at 12:30 p.m. Eastern Time.... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 16, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Martine Rothblatt, Ph.D. , Chairperson and Chief Executive Officer, will provide an overview and update on the company during a fireside chat session at the Bernstein 2 nd Annual Healthcare Forum in New York. The session will take place on... Read More

Results of the successful phase 3 TETON-2 study of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented in an oral presentation SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 12, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the European... Read More

Positive results were observed across all subgroups Study meets several key secondary endpoints with statistical significance SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 02, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that its TETON-2 study evaluating the use of nebulized Tyvaso® (treprostinil) Inhalation Solution for the treatment of... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Aug 29, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that James Edgemond , Chief Financial Officer and Treasurer, will provide an overview and update on the company’s operations during a fireside chat session at the Morgan Stanley 23 rd Annual Global Healthcare Conference in New York. The session will... Read More

Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Aug 01, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced that it will enter today into two Accelerated Share Repurchase ( ASR ) agreements with Citibank, N.A. ( Citi ) to repurchase an aggregate $1... Read More

Record total revenue of $799 million, reflecting 12 percent growth over the second quarter of 2024 and 12 consecutive quarters of double-digit, year-over-year total revenue growth Share repurchase of up to $1 billion authorized by the Board of Directors, expiring March 31, 2026 Tyvaso DPI® record total revenue of $315 million, reflecting 22 percent growth over the second quarter of 2024; no other commercially available... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jul 16, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its second quarter 2025 financial results before the market opens on Wednesday, July 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast... Read More

A phase 1 study of miroliverELAP for the treatment of acute liver failure is currently underway; 1 first patient in the study underwent the procedure at Intermountain Medical Center in Murray, Utah Approximately 30% of acute liver failure (ALF) patients die without access to a liver transplant. 2 EDEN PRAIRIE, Minn. & MURRAY, Utah / Jun 24, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public... Read More

Ralinepag has the potential to be the first once-a-day oral prostacyclin agonist for patients with pulmonary arterial hypertension ADVANCE OUTCOMES will continue to accrue clinical worsening events through the end of 2025 and top-line data is expected in the first half of 2026 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jun 23, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 30, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2025. Total revenues in the first quarter of 2025 grew 17 percent year-over-year to $794.4 million, compared to $677.7 million in the first quarter of 2024. “2025 is off to a tremendous start as... Read More

Interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open-label study to be presented at a mini symposium An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 21, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq:... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 16, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2025 financial results before the market opens on Wednesday, April 30, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 04, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that ten posters and presentations across its commercial and development portfolio will be presented at the International Society for Heart and Lung Transplantation ( ISHLT ) 45 th Annual Meeting and Scientific Sessions taking place April 27 through... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 02, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Great Place to Work® and Fortune magazine recognized the company as one of the Fortune 100 Best Companies to Work For® in 2025. United Therapeutics ranked number 73 out of the 100 companies across the nation included in the list. “We are honored... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Mar 04, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that James Edgemond , Chief Financial Officer and Treasurer, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Healthcare Conference 2025 in Miami Beach. The session will... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 26, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2024. Full year 2024 revenues rose to a record $2.88 billion, reflecting 24% growth over 2023. “I want to congratulate every Unitherian for their relentless dedication, which has... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 24, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Michael Benkowitz , President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 45 th Annual Health Care Conference in Boston. The session will take place... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 19, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its fourth quarter and full year 2024 financial results before the market opens on Wednesday, February 26, 2025. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a... Read More

Over 100,000 patients in the United States have IPF, with only two approved therapies available that only slow the course of disease progression Top line data expected in the first half of 2026 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 04, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced full enrollment of the TETON 1 study evaluating the use of... Read More

First-ever human clinical trial of a xeno-organ intended to allow for potential registration through the submission of a Biologics License Application to the U.S. FDA First xenotransplant is expected to occur around mid-year 2025 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 03, 2025 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that the U.S. Food... Read More

Posters include real-world dosing of Tyvaso DPI ® in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, and data from the BREEZE open-label extension study of Tyvaso DPI detailing its long-term outcomes and dosing in patients with pulmonary arterial hypertension United Therapeutics is sponsoring the Women in PH Luncheon and the Career Catalyst Luncheon: Speed Mentoring for... Read More

The first living recipient of a UKidney™ is recovering after a successful transplant This transplant builds on two successful UHeart™ transplants completed in 2022 and 2023 and a successful UThymoKidney™ transplant in 2024 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Dec 17, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the world’s first... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Nov 05, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the UBS Global Healthcare Conference in Rancho Palos Verdes, CA. The session will... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Oct 30, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2024. Total revenues in the third quarter of 2024 grew 23 percent year-over-year to $748.9 million, compared to $609.4 million in the third quarter of 2023. "I’m proud of the close to 1,300... Read More

Unique centralized service helps increase the supply of lungs for transplant, addressing a critical unmet need SILVER SPRING, Md. & JACKSONVILLE, Fla. / Oct 23, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. ( LBE ) announced that the 500 th lung transplant utilizing LBE’s centralized ex vivo lung perfusion ( EVLP ) service was... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Oct 23, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its third quarter 2024 financial results before the market opens on Wednesday, October 30, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast... Read More

Data from the BREEZE open-label extension study of Tyvaso DPI® detail its long-term outcomes and dosing in patients with pulmonary arterial hypertension United Therapeutics is sponsoring the Tyvaso DPI®: Clinical Pearls and Drug-Device Characteristics Symposium SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 24, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation,... Read More

Report available at www.corporateresponsibility.unither.com SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 10, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its 2024 Corporate Responsibility and Public Benefit Report ( Report ) covering its FY 2023 progress toward its public benefit goals and objectives and summarizing its... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Aug 28, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that company executives will present overviews and updates on the company’s operations during fireside chat sessions at two upcoming investor conferences. Michael Benkowitz , President and Chief Operating Officer, will present at the Morgan Stanley... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jul 31, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023. “This quarter we drove record revenue... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jul 24, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2024 financial results before the market opens on Wednesday, July 31, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast... Read More

Over 100,000 patients in the United States have IPF, with two approved therapies available that only slow the course of disease progression Top line data expected in the second half of 2025 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jul 10, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced full enrollment of the TETON 2 study evaluating the use of Tyvaso®... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jun 27, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced the addition of former Minnesota Commissioner of Health Jan Malcolm to its Board of Directors. Ms. Malcolm was elected by the company’s shareholders at its... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jun 05, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Goldman Sachs 45 th Annual Global Healthcare Conference in Miami Beach,... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / May 01, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023. “The first quarter of 2024 represents... Read More

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 26, 2024 / Business Wire / Please replace the photo... Read More

The first living recipient of a UThymoKidney, in conjunction with a heart pump implant, is recovering after a successful transplant This transplant builds on two successful UHeart transplants completed in 2022 and 2023 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 24, 2024 / Business Wire / United Therapeutics... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 24, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time. United Therapeutics will host a public webcast... Read More

Initial, interim long-term data from the ongoing ralinepag phase 3 ADVANCE EXTENSION open label study to be presented at a poster discussion session An annual update of the preliminary baseline data from the TETON phase 3 studies of inhaled treprostinil in idiopathic pulmonary fibrosis will be presented at a poster session SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 16, 2024 / Business Wire / United Therapeutics... Read More

Review manuscript available in the journal Physiological Reviews SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Mar 26, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the online availability of a review manuscript titled “Physiological Basis for Xenotransplantation from Genetically-Modified Pigs to Humans: A Review,” in the journal Physiological... Read More

Repurchase reflects the strength of United Therapeutics’ balance sheet and confidence in its near-term prospects SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Mar 25, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced that its Board of Directors has authorized the company to purchase up to $1 billion of United Therapeutics’ common stock. This program... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Mar 05, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s operations during a fireside chat session at the Leerink Partners Global Biopharma Conference 2024 in Miami Beach, Florida.... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 27, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Michael Benkowitz , President and Chief Operating Officer, will provide an overview and update on the company’s operations during a fireside chat session at the TD Cowen 44 th Annual Health Care Conference in Boston. The session will take place... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter and year ended December 31, 2023. Full year 2023 revenues rose to a record $2.33 billion, reflecting 20% growth over 2022. “Congratulations to the dedicated Unitherians who worked tirelessly to help us achieve... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 21, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today the commencement of litigation with the United States Food and Drug Administration ( FDA ). In the litigation, United Therapeutics alleges that the FDA mistakenly permitted Liquidia Corporation ( Liquidia ) to skirt longstanding FDA rules, precedents, and procedures on how pending... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 14, 2024 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 21, 2024. United Therapeutics will host a public webcast Wednesday, February 21, 2024, at 9:00 a.m. Eastern Time. The webcast will be accessible via United... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Dec 29, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42 nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn. / Dec 13, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today that United Therapeutics, through its wholly owned subsidiary Morpheus Subsidiary Inc. (“ Merger Sub ”), has successfully completed the previously announced tender offer to acquire all outstanding shares of... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn. / Dec 12, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today the results of the previously announced tender offer by Morpheus Subsidiary Inc. (“ Merger Sub ”), a wholly owned subsidiary of United Therapeutics, to acquire all outstanding shares of Miromatrix for a purchase... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Dec 07, 2023 / Business Wire / United Therapeutics (Nasdaq: UTHR ), a public benefit corporation, today announced that the company has been named on Newsweek’s list of America’s Most Responsible Companies 2024 . This award is presented by Newsweek and Statista Inc., the world-leading statistics portal and industry ranking provider. The list of awards was announced on... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Nov 01, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2023. Total revenues in the third quarter of 2023 grew 18% year-over-year to $609.4 million, compared to $516.0 million in the third quarter of 2022. “It’s a testament to our innovative... Read More

Up to 60,000 patients in the United States may have PPF, with only one approved therapy available SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Oct 31, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso® (treprostinil) Inhalation Solution... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., / Oct 31, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Conference 2023 in Miami Beach, Florida. The session will take... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. & EDEN PRAIRIE, Minn. / Oct 30, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human cells. United Therapeutics is a... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Oct 25, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. United Therapeutics will host a public webcast Wednesday, November 1, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics'... Read More

Second UHeart™ recipient recovering after a successful transplant UThymoKidney™ demonstrates normal function during a 61-day study Human xenotransplant clinical studies could begin in 2025 SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 22, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced the achievement of two milestones for its xenotransplantation... Read More

Report available at corporateresponsibility.unither.com SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 12, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation ( PBC ), today announced the release of its 2023 Corporate Responsibility and Public Benefit Report covering its 2022 progress toward its public benefit goals and objectives and summarizing its efforts to... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Sep 01, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that James Edgemond , Chief Financial Officer and Treasurer, will provide an overview and update on the company’s business during a fireside chat session at the Morgan Stanley 21st Annual Global Healthcare Conference in New York City. The session... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Aug 02, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2023. Total revenues in the second quarter of 2023 grew 28% year-over-year to $596.5 million, compared to $466.9 million in the second quarter of 2022. “I’m thrilled that United Therapeutics... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jul 26, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its second quarter 2023 financial results before the market opens on Wednesday, August 2, 2023. United Therapeutics will host a public webcast Wednesday, August 2, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Jul 24, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the United States Court of Appeals for the Federal Circuit affirmed the district court decision in the patent litigation United Therapeutics brought against Liquidia Technologies, Inc. The Federal Circuit affirmed that Liquidia’s proposed... Read More

First-of-its-kind distribution and warehouse center introduces a holistic approach to operations and energy management Facility poised to support United Therapeutics’ near-term growth objective of doubling its revenue run rate to $4 billion annually by the middle of this decade Opening event featured United Therapeutics’... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / May 03, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2023. Total revenues in the first quarter of 2023 grew 10% year-over-year to $506.9 million, compared to $461.9 million in the first quarter of 2022. “The hard work and determination of our over... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Apr 26, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ) announced today that it will report its first quarter 2023 financial results before the market opens on Wednesday, May 3, 2023. United Therapeutics will host a public webcast Wednesday, May 3, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United Therapeutics' website at... Read More

Results from the EXPEDITE study of Remodulin ® induction prior to Orenitram ® therapy to be presented at ATS Baseline patient data from the TETON studies of Tyvaso ® Inhalation Solution in patients with idiopathic pulmonary fibrosis to be presented at ATS ATS presentation examines geographical barriers as a social determinant of health for PAH patients; demonstrates UT’s commitment to reducing barriers to PAH care Data on... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Mar 06, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the Oppenheimer 33 rd Annual Healthcare Conference. The session will take place on... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 28, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Michael Benkowitz , President and Chief Operating Officer, will provide an overview and update on the company’s business during a fireside chat session at the Cowen 43 rd Annual Health Care Conference in Boston. The session will take place on... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 22, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the fourth quarter and year ended December 31, 2022. Full year total revenues rose to a record $1.94 billion, as U.S. patients being treated with the company’s treprostinil-based therapies reached an all-time high during the... Read More

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. / Feb 15, 2023 / Business Wire / United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2022 financial results before the market opens on Wednesday, February 22, 2023. United Therapeutics will host a public webcast Wednesday, February 22, 2023, at 9:00 a.m. Eastern Time. The webcast will be accessible via United... Read More

United Therapeutics Corporation (Nasdaq: UTHR ) announced today that Dr. Martine Rothblatt , Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a fireside chat session at the 41 st annual J.P. Morgan Healthcare Conference in San Francisco. The session will take place on Monday, January 9, 2023, from 1:30 p.m. to 2:10 p.m., Pacific Standard Time, and can be accessed... Read More